The global liver disease treatment market size reached USD 25.1 Billion in 2024. Looking forward, the market is projected to reach USD 40.4 Billion by 2033, exhibiting a growth rate (CAGR) of 5.44% during 2025-2033. The growing elderly population worldwide, which is prone to several chronic illnesses, including liver disease, is stimulating the market.
The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.
2. What is the expected growth rate of the global liver disease treatment market during 2025-2033?
3. What are the key factors driving the global liver disease treatment market?
4. What has been the impact of COVID-19 on the global liver disease treatment market?
5. What is the breakup of the global liver disease treatment market based on the treatment type?
6. What is the breakup of the global liver disease treatment market based on the disease type?
7. What is the breakup of the global liver disease treatment market based on the end user?
8. What are the key regions in the global liver disease treatment market?
9. Who are the key players/companies in the global liver disease treatment market?
The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.
Liver Disease Treatment Market Trends:
The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.Market Segmentation:
This report provides an analysis of the key trends in each segment of the market, along with the market forecasts at the global, regional, and country levels for 2025-2033. The report categorizes the market based on treatment type, disease type, and end user.Breakup by Treatment Type:
- Antiviral Drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
Breakup by Disease Type:
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
Breakup by End User:
- Hospitals
- Ambulatory Surgical Centers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.Key Questions Answered in This Report
1. What was the size of the global liver disease treatment market in 2024?2. What is the expected growth rate of the global liver disease treatment market during 2025-2033?
3. What are the key factors driving the global liver disease treatment market?
4. What has been the impact of COVID-19 on the global liver disease treatment market?
5. What is the breakup of the global liver disease treatment market based on the treatment type?
6. What is the breakup of the global liver disease treatment market based on the disease type?
7. What is the breakup of the global liver disease treatment market based on the end user?
8. What are the key regions in the global liver disease treatment market?
9. Who are the key players/companies in the global liver disease treatment market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Liver Disease Treatment Market
6 Market Breakup by Treatment Type
7 Market Breakup by Disease Type
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | May 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 25.1 Billion |
| Forecasted Market Value ( USD | $ 40.4 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
